India's semiconductor push

These 10 firms are advancing India's semiconductor push under the national mission, focusing on foundry, OSAT packaging/testing, and design rather than cutting-edge global nodes yet.


Tata Electronics leads with a major pure-play fab in Dholera (partnered with PSMC) for 28-110nm chips, plus packaging. 

Kaynes Semicon, 

CG Semi (CG Power JV with Renesas), 

SPEL, 

Sahasra,

 RRP, 

and HCL-Foxconn handle assembly/testing of modules, memory, and display drivers. 

MosChip and Polymatech add design and opto/materials expertise;

 VVDN supports via product engineering.


Together they build domestic capacity in assembly, packaging, and mature-node production to cut import reliance.

=====

Which of these are listed?

1. NSE Listed Companies (Directly Traded on NSE)

 * CG Power (CG Semi): Listed on NSE under ticker CGPOWER (The project is carried out via its joint venture CG Semi Private Limited).

 * SPEL Semiconductor: Listed on NSE under ticker SPELS.

 * MosChip Technologies: Listed on NSE under ticker MOSCHIP.

 * Sahasra: Listed on the NSE SME platform under ticker SAHASRA (listed via Sahasra Electronic Solutions Ltd).

2. NSE Listed via Parent / Holding Companies

 * Kaynes Semicon: Owned by Kaynes Technology India Ltd, which is listed on NSE under ticker KAYNES.

 * Tata Electronics: Unlisted private entity within the Tata Group network.

 * HCL-Foxconn (JV): Unlisted joint venture; the primary listed HCL entity on NSE is HCL Technologies Ltd (HCLTECH).

3. Unlisted / Non-NSE Entities

 * RRP Electronics: Not listed on NSE (listed only on BSE under ticker 504746 as RRP Electronics India Ltd).

 * Polymatech Electronics: Unlisted private company.

 * VVDN Technologies: Unlisted pri

vate company.

Comments

Post a Comment

Popular posts from this blog

LT investing. Pharma. How to shortlist stocks to make a balanced portfolio

 Used Gemini. prompts and outputs are given below. My comments are marked 'mk'. This is a single thread. prompt:  what are different types of pharma stocks like cdmo, generic producers etc. in plain text <500 words. output: The pharmaceutical sector is divided into distinct business models based on where companies operate along the drug value chain. Understanding these categories helps clarify how they generate revenue and manage risk. Generics and Branded Generics These companies manufacture exact copies of off-patent chemical drugs. Their business model relies on high-volume, low-cost production to capture market share globally. While demand is steady due to constant patent expirations, they face heavy price erosion from intense competition and strict regulatory audits. Examples include Sun Pharma, Dr. Reddy's, and Teva. Active Pharmaceutical Ingredients (APIs) API manufacturers produce the raw chemical or biological bulk components that give medicines their therapeuti...
Read more

Peter Thiel’s rules

Peter Thiel’s rules emphasize spotting unique, durable businesses rather than chasing cheap valuations. His framework guides investors to focus on philosophy, quality, moats, niche dominance, independent thinking, reinvestment, and long-term conviction.   Ref https://m.economictimes.com/markets/stocks/news/peter-thiels-7-timeless-rules-for-spotting-winning-businesses-here-is-what-investors-must-know/articleshow/133435143.cms --- 📌 Peter Thiel’s Rules Major 3 rules: - Business philosophy     Look beyond financial metrics. Companies built on strong values, clear missions, and disciplined execution create sustainable long‑term value.   - Quality over cheap valuations     Don’t chase low prices. Prioritize strong balance sheets, cash generation, competitive positioning, and capital allocation.   - Durable competitive advantages     Back “creative monopolies” — firms with proprietary tech, network effects, power...
Read more

Major Periods of Notable Pullbacks in Nifty 50

The Nifty 50 index, launched in 1996, has seen numerous pullbacks—temporary declines from recent highs—amid global events, domestic policies, and economic shifts. "Notable" pullbacks here refer to corrections of 10% or more, with a focus on significant ones exceeding 20% (often classified as bear markets). These occur roughly every 2-3 years on average, with historical data showing about 19 such 10%+ corrections in the last 16 years (average depth ~14%) and 8 bear markets in 25 years (average depth 38.5%, lasting ~246 days to bottom). Below is a curated table of key notable pullback periods, primarily bear markets (>20% decline), compiled from reliable historical analyses. I've included peak-to-trough timelines, percentage drawdowns, durations to bottom, and major triggers where known. For brevity, this focuses on the most impactful; smaller 10-20% corrections (e.g., mid-2018 global trade tensions or late-2021 FII outflows) occur annually but are less transformative. P...
Read more